CY1123116T1 - Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα - Google Patents
Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματαInfo
- Publication number
- CY1123116T1 CY1123116T1 CY20201100635T CY201100635T CY1123116T1 CY 1123116 T1 CY1123116 T1 CY 1123116T1 CY 20201100635 T CY20201100635 T CY 20201100635T CY 201100635 T CY201100635 T CY 201100635T CY 1123116 T1 CY1123116 T1 CY 1123116T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- therapeutic treatment
- autoimmune disorders
- autoimmune
- antibody
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μια μέθοδο θεραπευτικής αντιμετώπισης μιας αυτοάνοσης ή φλεγμονώδους νόσου ή μιας νευροεκφυλιστικής νόσου με ένα αντίσωμα στο CD154.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1501613.2A GB201501613D0 (en) | 2015-01-30 | 2015-01-30 | Treatment of autoimmune disorders with CD154 antibodies |
PCT/EP2015/059095 WO2016119909A1 (en) | 2015-01-30 | 2015-04-27 | Treatment of autoimmune disorders with cd154 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123116T1 true CY1123116T1 (el) | 2021-10-29 |
Family
ID=52705552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100635T CY1123116T1 (el) | 2015-01-30 | 2020-07-10 | Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα |
Country Status (19)
Country | Link |
---|---|
US (2) | US20180022812A1 (el) |
EP (2) | EP3744735A1 (el) |
KR (1) | KR102543877B1 (el) |
CN (1) | CN107206075A (el) |
AU (2) | AU2015379642B2 (el) |
CA (1) | CA2975336C (el) |
CY (1) | CY1123116T1 (el) |
DK (1) | DK3250600T3 (el) |
ES (1) | ES2802982T3 (el) |
GB (1) | GB201501613D0 (el) |
HR (1) | HRP20201013T1 (el) |
HU (1) | HUE050024T2 (el) |
LT (1) | LT3250600T (el) |
PL (1) | PL3250600T3 (el) |
PT (1) | PT3250600T (el) |
RS (1) | RS60575B1 (el) |
RU (1) | RU2695443C2 (el) |
SI (1) | SI3250600T1 (el) |
WO (1) | WO2016119909A1 (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2683406B1 (en) | 2011-03-11 | 2019-05-08 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
US11099185B2 (en) * | 2016-02-29 | 2021-08-24 | Maintect Gmbh | Predictive markers useful in the treatment of wet age-related macular degeneration |
AU2019347730A1 (en) * | 2018-09-24 | 2021-03-25 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-CD154 antibody |
CN114895041A (zh) * | 2021-07-01 | 2022-08-12 | 浙江大学 | 一种检测抗蛋白酶体亚基α1-IgG抗体的试剂盒 |
KR20240109277A (ko) * | 2021-12-01 | 2024-07-10 | 유씨비 바이오파마 에스알엘 | Fab-peg를 포함하는 제제 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
BRPI0809042B1 (pt) | 2007-03-22 | 2021-08-31 | Biogen Ma Inc. | Proteína de ligação a cd154 isolada, seu uso, e composição |
EP2367849B1 (en) * | 2008-12-05 | 2017-11-01 | ALS Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
EP2701742A4 (en) | 2011-04-26 | 2015-03-18 | Genentech Inc | COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES |
-
2015
- 2015-01-30 GB GBGB1501613.2A patent/GB201501613D0/en not_active Ceased
- 2015-04-27 RU RU2017130464A patent/RU2695443C2/ru active
- 2015-04-27 EP EP20172402.8A patent/EP3744735A1/en active Pending
- 2015-04-27 SI SI201531299T patent/SI3250600T1/sl unknown
- 2015-04-27 AU AU2015379642A patent/AU2015379642B2/en active Active
- 2015-04-27 LT LTEP15719675.9T patent/LT3250600T/lt unknown
- 2015-04-27 WO PCT/EP2015/059095 patent/WO2016119909A1/en active Application Filing
- 2015-04-27 DK DK15719675.9T patent/DK3250600T3/da active
- 2015-04-27 PT PT157196759T patent/PT3250600T/pt unknown
- 2015-04-27 HU HUE15719675A patent/HUE050024T2/hu unknown
- 2015-04-27 CA CA2975336A patent/CA2975336C/en active Active
- 2015-04-27 KR KR1020177024036A patent/KR102543877B1/ko active IP Right Grant
- 2015-04-27 US US15/547,223 patent/US20180022812A1/en not_active Abandoned
- 2015-04-27 EP EP15719675.9A patent/EP3250600B1/en active Active
- 2015-04-27 CN CN201580074799.1A patent/CN107206075A/zh active Pending
- 2015-04-27 ES ES15719675T patent/ES2802982T3/es active Active
- 2015-04-27 RS RS20200831A patent/RS60575B1/sr unknown
- 2015-04-27 PL PL15719675T patent/PL3250600T3/pl unknown
-
2020
- 2020-06-26 HR HRP20201013TT patent/HRP20201013T1/hr unknown
- 2020-07-10 CY CY20201100635T patent/CY1123116T1/el unknown
-
2021
- 2021-06-29 US US17/361,393 patent/US11884737B2/en active Active
-
2022
- 2022-01-19 AU AU2022200347A patent/AU2022200347A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HUE050024T2 (hu) | 2020-11-30 |
GB201501613D0 (en) | 2015-03-18 |
AU2015379642A1 (en) | 2017-07-27 |
US11884737B2 (en) | 2024-01-30 |
NZ733454A (en) | 2023-12-22 |
KR20170106476A (ko) | 2017-09-20 |
LT3250600T (lt) | 2020-07-27 |
WO2016119909A1 (en) | 2016-08-04 |
AU2015379642B2 (en) | 2021-11-04 |
HRP20201013T1 (hr) | 2020-10-16 |
SI3250600T1 (sl) | 2020-09-30 |
EP3250600B1 (en) | 2020-05-06 |
RU2695443C2 (ru) | 2019-07-23 |
RU2017130464A (ru) | 2019-02-28 |
PL3250600T3 (pl) | 2020-09-21 |
DK3250600T3 (da) | 2020-06-08 |
US20180022812A1 (en) | 2018-01-25 |
PT3250600T (pt) | 2020-06-17 |
RS60575B1 (sr) | 2020-08-31 |
RU2017130464A3 (el) | 2019-02-28 |
ES2802982T3 (es) | 2021-01-22 |
AU2022200347A1 (en) | 2022-02-17 |
US20210324095A1 (en) | 2021-10-21 |
KR102543877B1 (ko) | 2023-06-14 |
CA2975336C (en) | 2022-10-18 |
EP3744735A1 (en) | 2020-12-02 |
EP3250600A1 (en) | 2017-12-06 |
CN107206075A (zh) | 2017-09-26 |
CA2975336A1 (en) | 2016-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123116T1 (el) | Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα | |
CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
EA202092435A2 (ru) | Моноклональные антитела против bcma | |
EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201691974A1 (ru) | Антитела против ox40 и способы их применения | |
EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
EA201890093A1 (ru) | Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина | |
EA201790802A1 (ru) | Соединения против tnf | |
DK3137504T3 (da) | Antistofbinding til fcrn til behandling af autoimmunsygdomme | |
BR112017009297A2 (pt) | anticorpos antifator de complemento c1q humanizados e usos dos mesmos | |
CY1122233T1 (el) | Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο | |
CY1124704T1 (el) | Παραγωγα sobetirome | |
CL2016001979A1 (es) | Métodos de tratamiento de enfermedad de alzheimer. | |
MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
GEP20227382B (en) | Anti-coagulation factor xi antibodies | |
EA201691541A1 (ru) | Новые анти-baff антитела | |
DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme |